Pyrazole derivatives as jak inhibitors

Disclosed herein is a pyrazole derivative compound of general formula (I), wherein the subsittuents are defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as JAK inhibitors, as such is useful in the treatment of a pathological condition or disease selected from myeloproliferative disorders, leukemia, lymphoid malignancies and solid tumors; bone marrow and organ transplant rejection; and immune-mediated diseases, or wherein the pathological condition or disease is selected from inflammatory diseases. Compounds of the invention include: (S)-N-(1-phenylethyl)-2-(pyrazolo[1,5-a]pyrazin-3-yl)pyrimidin-4-amine, 3-{ (3R)-3-[Methyl(2-pyrazolo[1,5-a]pyrazin-3-ylpyrimidin-4-yl)amino]piperidin-1-yl} -3-oxopropanenitrile and 2-(Pyrazolo[1,5-a]pyrazin-3-yl)-N4-(tetrahydro-2H-pyran-4-yl)pyrimidine-4,5-diamine